Select Medical Holdings (SEM) shareholders have voted to approve the go-private merger backed by company insiders and private equity firm Welsh, Carson, Anderson & Stout (WCAS). The transaction would take SEM off public markets, and the shareholder vote represents a significant procedural hurdle now cleared. Exact deal price terms were not re-stated in the headline, but with the vote passed, the path to closing has materially de-risked.

SEM is a sizable healthcare services operator with roughly $5.5B in annual revenue growing at 5.1% year-over-year, though net margins are thin at 3.9% and diluted EPS sits at $1.16. The insider-led nature of the deal — with management and WCAS as the acquirer group — reduces the risk of a strategic bidder emerging to break the deal, but it also means shareholders are locked into the negotiated terms.

For traders, this is now a classic merger-arb setup: the question is how much spread remains between the current stock price and the deal consideration, and what residual deal-break risk justifies that spread. With shareholder approval in hand, the remaining risks are regulatory sign-off and financing close.

The bull case for arb longs is straightforward — shareholder approval is the biggest vote-of-confidence milestone, and insider + PE backing reduces deal-break probability sharply. The bear case centers on any lingering regulatory review timeline or financing conditions that could delay or derail closing, which would expose the stock to a significant re-rating back toward fundamental value on thin 3.9% net margins.